NCT04671069View on ClinicalTrials.gov

Drug Interaction Study of MGL-3196 With Clopidogrel

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 26, 2019

Primary Completion Date

August 30, 2019

Study Completion Date

September 14, 2019

Conditions
Healthy
Interventions
DRUG

MGL-3196

Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14

DRUG

Clopidogrel

After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Madrigal Pharmaceuticals, Inc.

INDUSTRY

NCT04671069 - Drug Interaction Study of MGL-3196 With Clopidogrel | Biotech Hunter | Biotech Hunter